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ABSTRACT
Background: Yoga interventions offer promise for the treatment of major depressive disorder
(MDD), yet their safety and potential impact on suicidal ideation (SI) have not been well
documented. This study evaluated the safety of a randomized controlled dose-finding trial of
Iyengar yoga plus coherent breathing for individuals with MDD, as well as the potential effects
of the intervention on SI without intent.
Methods: Participants with Beck Depression Inventory-II (BDI-II) scores ≥ 14 and a diagnosis
of MDD (using DSM-IV criteria) were randomized to either a low dose group (LDG) or high
dose group (HDG) and received a 12-week manualized intervention. The LDG included two

90-minute yoga classes plus three 30-minute homework sessions weekly. The HDG offered
three 90-minute classes plus four 30-minute homework sessions weekly.
Results: Thirty-two individuals with MDD were randomized, of which 30 completed the
protocol. At screening, SI without intent was endorsed on the BDI-II by 9 participants; after
completing the intervention, 8 out of 9 reported resolution of SI. There were 17 adverse events
possibly-related and 15 definitely-related to the intervention. The most common protocolrelated adverse event was musculoskeletal pain, which resolved over the course of the study.
Conclusions: The Iyengar yoga plus coherent breathing intervention was associated with the
resolution of SI in 8 out of 9 participants, with mild side effects that were primarily
musculoskeletal in nature. This preliminary evidence suggests that this intervention may
reduce SI without intent and be safe for use in those with MDD.
INTRODUCTION
Major depressive disorder (MDD) is a common, recurrent, often chronic and disabling disorder(1).
Depression is globally responsible for more years lost to disability than any other disease(2). Up to 40%
of individuals with MDD treated with antidepressant medication do not achieve full remission(3).
Moreover, residual symptoms of depression are associated with increased risk of recurrence and
relapse(4). Data from randomized controlled trials (RCTs) indicate that yoga holds promise as an
effective intervention for the treatment of depression(5–8). However, the safety of yoga, including effects
on suicidal ideation (SI), have not been well studied in individuals with MDD.
A meta-analysis and review of 12 RCTs (N=619) using yoga for the treatment of depression
found that yoga was significantly better than usual care, relaxation exercises, and aerobic exercise.
However, this same review noted that there were no published reports of safety data from RCTs. In a
recent meta-analysis of 92 RCTs across a broad range of conditions, yoga was not associated with
increased frequency of intervention-related non-serious or serious adverse events compared to
exercise or usual care. However, when compared to non-physical interventions, such as psychological
or educational interventions, yoga was associated with increased frequency of intervention related nonserious adverse events; serious adverse events were rare(5). There is a need for specific safety data for
yoga-based interventions in MDD.
There are no known studies evaluating the use of an Iyengar yoga and coherent breathing
intervention (yoga intervention) for SI. This manuscript presents a follow-up analysis of an RCT of a 12week yoga intervention for individuals with MDD. The primary study found that both the low dose group
(LDG; 2x weekly + homework) and high dose group (HDG; 3x weekly + homework) were associated
with decreased Beck Depression Inventory-II (BDI-II) scores consistent with response (50% reduction
in BDI-II scores) and remission (BDI-II < 14)(9). This manuscript has two aims: 1) to evaluate the effects
of the intervention on SI without intent in participants with MDD, and 2) to assess the safety of the
intervention. Musculoskeletal AEs were anticipated based on previous reports(10,11).
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MATERIALS AND METHODS
We present SI data and safety findings from a parent study described in a previous report(9), conducted
October 2013 - September 2015 at the Boston University Medical Center (BUMC), and approved by
their Institutional Review Board (IRB). Recruitment was conducted in the community with flyers,
newspaper advertisements, and the internet. Baseline data were collected prior to randomization. A
rolling admissions design was utilized; participants entered the 12-week intervention to which they were
randomized using a permuted block design (n=4). A blinded statistician (with no participant contact)
placed group assignments in sealed envelopes, sequentially opened when a participant was
randomized.
Intervention: Participants were randomized to either a LDG or a HDG. The LDG was assigned
two 90-minute classes and three 30-minute homework sessions per week. The HDG was
assigned three 90-minute classes and four 30-minute homework sessions per week.
Homework consisted of 15-minutes of Iyengar yoga followed by 15-minutes of coherent
breathing. Each 90-minute class included approximately 60-minutes of Iyengar yoga postures,
10-minutes of transition including deep relaxation, and 20-minutes of coherent breathing,
paced by a chime tone recording on a compact disc. Iyengar yoga emphasizes correct
alignment while performing postures. Coherent breathing entails breathing through the nose
with equal duration of inhalation and exhalation at a rate of 5 breaths per minute. These
practices have been shown to optimize heart rate variability (HRV) and sympatho-vagal
balance(12–14). Further details of this same intervention were previously reported(9).
Instructor Training and Intervention Fidelity: All instructors completed an Iyengar Introductory Level II
certification exam (≥ 2 years of study), had >5 years teaching experience, used the intervention
manual, received training in coherent breathing, were assessed quarterly by the Principal Investigator
(PI) using a protocol compliance fidelity instrument. There were 15 fidelity assessments on 5 instructors
that documented fidelity to the assessment categories. Instructors were trained and allowed to modify
the sessions to meet the needs of the participants, which included the use of props (e.g., blocks,
blankets, and straps). The protocol encouraged instructors to modify the classic postures such that
participants could be successful in their attempts while also minimizing injuries.
Instruments: The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) was used at
screening to confirm the diagnosis of MDD and assess for other Axis I disorders(15). The Beck
Depression Inventory-II (BDI-II), a 21-item, self-rated questionnaire, measured depressive
symptoms(16). Scoring criteria: minimal depression 0-13, mild depression 14-19, moderate depression
20-28, and severe depression 29-63. BDI-II question #9 assessed SI with the following response
options: 0) I don’t have any thoughts of killing myself; 1) I have thoughts of killing myself, but I would
not carry them out; 2) I would like to kill myself; and 3) I would kill myself if I had the chance.
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-administered
assessment(17). At screening, the C-SSRS form was used for two time frames: 1) “lifetime”, and 2) “last
year” (rather than the standard time frame of “past month”). At weeks 4, 8, and 12, a “since the last
visit” time frame was used. The C-SSRS SI section uses the following items: 1) wish to be dead, “Have
you wished you were dead or wished you could go to sleep and not wake up?”; 2) non-specific active
suicidal thoughts, “Have you actually had any thoughts of killing yourself?”; 3) active suicidal ideation
with any method (not plan) without intent to act, ”Have you been thinking about how you might do
this?”; 4) active suicidal ideation with some intent to act; without specific plan; and 5) active suicidal
ideation with specific plan and intent. Affirmative answers to items 4 or 5 during screening were
exclusionary.
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The Weekly Safety Form contained the following questions: 1) “Are you feeling more
depressed?”; 2) “Are you feeling suicidal?”; 3) “Mark your level of depression in the last week –
response options: none, mild, moderate, severe”; 4) “Have you had any muscle soreness?”; and 5)
“Have you had any other adverse events this week? (Adverse events are new or worsening medical
problems.) If so, please list them.” Participants returned completed Weekly Safety Forms at the
beginning of each calendar week of the intervention. As the 12-week intervention could occur over 13
calendar weeks, each participant could complete a maximum of 13 Weekly Safety Forms.
Clinical evaluations by a psychiatrist (PI) at baseline and a psychiatrist (PI) or clinical
psychologist at weeks 4, 8, and 12 included a review of Weekly Safety Forms, BDI-II, and C-SSRS.
Additional clinical assessments by a psychiatrist or clinical psychologist were triggered by any 4-point
increase on BDI-II, worsening depression or suicidality on the Weekly Safety Forms, staff observations
of participant distress, or participant reports of distress. The BDI-II was only given during assessment
visits, when the participant also had a clinical and safety assessment. Adverse events (AEs) were
defined as new or worsening medical problems that increased by one level of severity. Severity level of
AEs was rated: 1) mild - does not have a major impact on the participant, 2) moderate - causes some
minor inconveniences, and 3) severe - causes substantial disruption to the participant. Adverse event
relationship to study was rated: 1) definitely-related, 2) possibly-related, and 3) not related. Pre-existing
conditions that continued in the pre-existing pattern were not considered AEs. All subjects had
depression at baseline, and depression was not reported as an AE unless a patient changed one level
of AE severity rating from their pre-existing baseline condition. Severity of AE and relationship to study
was determined by the study PI, a board-certified psychiatrist and neurologist.
Original Inclusion and Exclusion Criteria: Participants met the following criteria: 18 to 55 years of age,
current SCID diagnosis of MDD, and at least mild depression based on BDI-II total score of 14-27 (≥ 28
indicates severe depression). Co-morbid anxiety disorders that would not interfere with study
participation were allowed. The following items were exclusionary: treatment with antidepressants;
psychotherapy for depression within 3 months of screening; more than 6 one-hour sessions of mindbody practices in the last 6 months; current prayer practice (>2 hours per week), as this could be
similar to meditation; diagnosis of bipolar illness or psychosis; lifetime history of a suicide attempt or SI
with or without intent within the last year (using C-SSRS criteria); current alcohol or substance abuse or
dependence; and inability to complete the study protocol.
Adjusted Inclusion and Exclusion Criteria: After the enrollment of 16 of the 32 participants, the inclusion
and exclusion criteria were liberalized because no serious AEs were observed, and individuals who
could potentially safely benefit from the intervention were being excluded by restrictive eligibility criteria.
The inclusion criteria were expanded to: 1) remove the BDI-II total score upper limit (<28) to include
individuals with more severe depressive symptoms; 2) increase the age limit from 55 to 65; and 3)
include participants on stable doses of antidepressant medications for at least three months with no
anticipated dosage change during the study. Exclusion criteria were expanded to allow SI without
intent, while still excluding SI with intent within the past year. This particular exclusion criterion was
liberalized consistent with the 2008-2012 US National Survey on Drug Use and Health, that found
past-month suicide attempts were far less common in those adults reporting SI without a plan in the
past 12-months compared to those who reported SI with a plan (3.7% to 37.0%, respectively)(18).
Statistical Methods: Study data were collected using Research Electronic Data Capture (REDCap).
Data were analyzed using SPSS version 24. P values for all statistical tests were two-tailed, using an
alpha of .05 for statistical significance, unless otherwise noted. Pearson Chi-Square tests were used to
compare LDG and HDG across categorical variables, such as SI vs. no SI, race, ethnicity, and gender.
Independent-Samples T-Tests were conducted to compare continuous demographic variables (e.g.,
age). If Levene’s Test for the Equality of Variances was violated, the degrees of freedom and p-values
were reported for equal variances not assumed and noted as such. Bivariate correlations were used to
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explore the relationship between total numbers of adverse events and age. AEs were not compared
between the LDG and HDG, because there were multiple AEs within participants, such that a discrete
denominator for the appropriate statistical test (i.e., generalized linear model [binomial model] allowing
multiple events within a single subject) could not be calculated.
RESULTS
Telephone screening yielded 265 participants; 86 participated in a screening visit, 32 were randomized,
and 30 completed the intervention (LDG: n=15; HDG: n=15). Subject flow chart was previously
provided(9). Only adverse events in participants who were randomized were reported. Two participants
(1 per arm) were lost to follow-up prior to the week-4 evaluation; they did not complete a BDI-II or CSSRS after screening and were not included in the analyses.
Baseline Demographics and Yoga Dose: There were no statistically significant differences in baseline
demographics (See Table 1). As reported in the primary manuscript(9), compliance with total assigned
class and homework minutes did not differ between groups (p=0.77): LDG 84% ± 19% and HDG 87% ±
28%. As expected, the HDG had significantly greater total (in class + homework time) yoga minutes
(4,075±1,314) compared to the LDG (2,737±625; p<0.001).
Table 1. Participant demographics
Demographic
Age (years)
Gender
(female/male)
Years of
Education
Ethnicity
Hispanic

LDG
(n=15)

HDG
(n=15)

t-test or χ2

p-value

34.7 + 10.4

38.4 + 15.1

t (24.84) = 0.79*

0.44

12/3

13/2

χ2(1) = 0.24

0.62

16.7 + 2.2

16.3 + 2.2

t (28) = 0.51

0.62

**n/a

**n/a

χ2(2) = 3.40

0.18

0/15

0/15

Race
Caucasian
African
American
Asian

13/15

10/15

2/15

2/15

0/15

3/15

*Violated Levene’s Test for Equality of Variances, reported for unequal variances.
** Could not complete statistical test due to zero participants per group.
LDG: Low Dose Group (two 90-minute yoga classes plus three 30-minute homework sessions weekly)
HDG: High Dose Group (three 90-minute classes plus four 30-minute homework sessions weekly)

This report focuses on AEs possibly- or definitely-related to the protocol. There were 17 individuals
responsible for the 32 possibly- or definitely-related mild AEs (See Table 2). The most common study
related AE, musculoskeletal pain, was anticipated and resolved during the study. Musculoskeletal pain
was reported in 16 out of 30 (53%) of participants: 12 reports were possibly-related and 13 were
definitely-related to the intervention. Table 2 provides a list of the participants who accounted for the
related AEs. Other than musculoskeletal pain, AEs possibly-related to the intervention included
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headaches, dizziness, and a nose bleed. One participant reported headaches when classes were held
in a room with a carpet. One participant had a nose bleed that did not require medical intervention,
which was likely an exacerbation of an existing condition due to inversions . Definitely-related AEs other
than musculoskeletal pain, included a headache and increased negative/ruminative thoughts
associated with use of the at home coherent breathing CD. The homework protocol was modified for
this participant to include 30-minutes of postures without breathing exercises, which resolved the
ruminative thoughts.
Table 2: Adverse events (AEs) possibly- and definitely-related to the study intervention
AE Number

Subject

Dose

Musculoskeletal Adverse
Events

Localization

Other Adverse
Event

Possibly Related
1

1

Low

Musculoskeletal Pain

Calf

2

1

Low

Musculoskeletal Pain

Left hip

3

1

Low

Musculoskeletal Pain

Midback

4

1

Low

Musculoskeletal Pain

Low back

5

2

Low

Musculoskeletal Pain

Low back & left groin

6

2

Low

Musculoskeletal Pain

Right shoulder

7

2

Low

Musculoskeletal Pain

Right groin

8

3

High

Musculoskeletal Pain

Neck

9

3

High

Musculoskeletal Pain

General

10

4

High

Musculoskeletal Pain

Left hip

11

5

High

Musculoskeletal Pain

Low back

12

6

High

Musculoskeletal Pain

Neck

13

7

Low

Headache

14

7

Low

Headache

15

7

Low

Headache

16

1

Low

Dizziness

17

8

High

Nose bleed
Definitely-Related

18

9

Low

Musculoskeletal Pain

Low back

19

9

Low

Musculoskeletal Pain

Low back

20

9

Low

Musculoskeletal Pain

Low back

21

10

Low

Musculoskeletal Pain

General

22

10

Low

Musculoskeletal Pain

General

23

11

Low

Musculoskeletal Pain

Arm

24

8

High

Musculoskeletal Pain

Low back

25

12

High

Musculoskeletal Pain

General

6

26

13

High

Musculoskeletal Pain

Ankle

27

14

Low

Musculoskeletal Pain

General

15

High

Musculoskeletal Pain

Arms and
Hamstrings

29

16

Low

Musculoskeletal Pain

Hamstrings

30

17

High

Musculoskeletal Pain

Low back

5

High

↑ Negative
thoughts

5

High

Headache

28

31
32

Out of a possible maximum of 390 Weekly Safety Forms (30 participants completing up to 13 forms
each), 366 (94%) were collected. The missing 6% occurred because some participants completed only
12 forms or did not turn in all scheduled forms. Twenty-three reports of worsening depression were
identified by the Weekly Safety Forms (“Are you feeling more depressed?”). Thirteen individuals were
responsible for the 23 reports of worsening depression. No subjects had an increase in the severity
level of their depressive symptoms using AE criteria. Accordingly, none of the problem endorsements of
worsening depression on the Weekly Safety forms were considered AEs based on the severity level of
AEs (defined in the Method Section). No evaluations found increased risk of self-harm, or worsening
functional impairment. No participants were withdrawn or referred for conventional treatment during the
study.
Reports of SI:
BDI-II: BDI-II question #9, item 1 (I have thoughts of killing myself, but I would not carry them out) was
endorsed by 9 participants at screening (4 LDG, 5 HDG), 4 at week-4 (2 LDG, 2 HDG), 1 at week-8 (1
HDG), and 1 at week-12 (1 HDG). At week-4, 1 participant (1 HDG) endorsed item 2 (I would like to kill
myself). This person was evaluated and found to have SI without intent (See Figure 1). Pearson ChiSquare revealed no differences at screen between the LDG and HDG on BDI-II item #9 zero versus
non-zero responses (X2(1)=.159, p=0.690).
Figure 1: Comparative number of participants endorsing suicidal ideation on Question #9 items 1 and 2 of the
Beck Depression Inventory-II

Legend: BDI-II question #9 assessed suicidal ideation severity:
Item 1) I have thoughts of killing myself, but I would not carry them out;
Item 2) I would like to kill myself.
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Figure 2: Suicidal ideation severity on the Columbia-Suicide Severity Rating Scale (CSSR-S)

Legend: 1) wish to be dead; item 2) non-specific active suicidal thoughts; item 3) active suicidal ideation with any
method (not plan) without intent to act.
Note: The total number of participants endorsing suicidality at each time point is equal to the total number for item
1. All participants who endorsed item 2 also endorsed item 1; all participants who endorsed item 3 also endorsed
items 1 and 2.

C-SSRS: The C-SSRS item 1 (passive SI) was endorsed by 10 participants at screening (5 LDG, 5
HDG), 5 at week-4 (1 LDG, 4 HDG), 2 at week-8 (2 HDG), and 1 at week-12 (1 HDG). Item 2 (SI
without intent) was endorsed by 5 participants at screening (3 LDG; 2 HDG), 2 at week-4 (2 HDG), 1 at
week-8 (1 HDG), and 0 at week 12. Item 3 (SI with any method without intent to act) was endorsed by 2
participants at screening (2 HDG). Participants who endorsed items greater than 1 also endorsed lower
item numbers as well, therefore the total number of participants reporting SI in any form equals the
number of participants endorsing item 1 (See Figure 2). Pearson Chi-Square revealed no differences
between the LDG and HDG at screen on C-SSRS passive SI responses (within the past year) when
comparing zero versus non-zero responses (X2(1)=.000, p=1.000).
Figure 2: Suicidal ideation severity on the Columbia-Suicide Severity Rating Scale (CSSR-S)

Legend: 1) wish to be dead; item 2) non-specific active suicidal thoughts; item 3) active suicidal ideation with any
method (not plan) without intent to act.
Note: The total number of participants endorsing suicidality at each time point is equal to the total number for item
1. All participants who endorsed item 2 also endorsed item 1; all participants who endorsed item 3 also endorsed
items 1 and 2.
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One participant at screening and one at week-8 endorsed SI on the CSSR-S but not on the BDI-II. The
CSSR-S at screen covered a longer time frame (“within the last year”) compared to the BDI-II (twoweeks). Also, the BDI-II only evaluated thoughts of killing oneself, whereas the CSSR-S has a more
nuanced evaluation of passive SI (i.e., thought of falling asleep and not waking up).
DISCUSSION
This study evaluated changes in SI without intent and overall safety of a LDG and HDG 12-week yoga
intervention for adults with MDD. As reported previously, the intervention was associated with
significantly decreased BDI-II total scores, demonstrating large effect sizes for both the LDG (Cohen’s d
= -1.89) and HDG (Cohen’s d = -2.81) with a significant correlation in the expected direction between
total number of yoga minutes and decreases on the BDI-II total score(9). Overall, SI resolved in all but
one participant and the intervention appeared to be tolerable, with musculoskeletal pain being the most
common AE, which resolved and was mild in nature. There were no serious adverse events related to
the protocol, nor did any subject need to be hospitalized or removed from the protocol due to worsening
depressive symptoms or SI.
Suicidal Ideation: Intervention participation was associated with decreases in SI for 8 of the 9
participants who reported SI without intent at screening. Out of the 30 participants, only one reported a
transient increase in rating of SI at week 4 (Figure 1). Decreased depressive symptoms and resolution
of suicidality were seen in all but one participant (HDG) who continued to endorse SI on BDI-II and CSSRS at week-12, while showing a decrease in BDI-II total score from 36 (severe depression) to 15
(mild depression).
While there is an assumed relationship between depressive symptoms and the presence of SI, there is
a need for explicit evaluations of the effect of treatments on SI(19). A systematic review and metaanalysis of RCTs in patients with MDD treated with serotonin selective reuptake inhibitors (SSRIs), with
a secondary outcome measures of suicide, suicide attempts, and SI did not find a significant
differences between participants randomized to placebo versus a SSRI for suicide (6 RCTs), suicide
attempts (8 RCTs) or SI (11 RCTs)(20).
The lack of compelling evidence that RCTs of SSRIs decrease suicide ideation is in contrast to the
findings of this study. These promising results need replication, given that this is the only study, to date,
documenting reductions in SI associated with a yoga-based intervention in an MDD population.
Safety/Adverse Events: Safe and effective alternatives to antidepressant medications are sorely
needed, given the significant AEs associated with antidepressant medications, such as: 1) the potential
for the exacerbation of suicidality(21,22); 2) the induction of agitated and/or mixed manic and
depressive states(23); 3) the burdensome common side effects (e.g., weight gain, sexual dysfunction,
fatigue)(24); and 4) the potential for medication misuse in suicide attempts. The purpose of this paper
was to understand what kind of AEs are common in a yoga-based intervention for depression and
whether these AEs would involve a clinician’s immediate attention or would cause worsening
psychiatric symptomatology. AEs in this study were mild with no serious intervention-related AEs; none
of which were present in this study. Based on the Weekly Safety Forms and clinician evaluations of
adverse events at weeks 4, 8, and 12 and the two-week follow-up phone call, all AEs were mild and all
but one possibly-related back pain resolved by the two-week follow-up. The most common AE,
musculoskeletal pain, was anticipated. There did not appear to be differences in musculoskeletal pain
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between the LDG or HDG (though we were not able to conduct statistical tests on these data; please
see Method Section), consistent with previous reports of dosage not being a determining factor in
increased adverse events in yoga trials(11). No participants dropped out of the study due to
musculoskeletal pain or any other AEs. Results indicated that yoga seemed tolerable to this population
of individuals with MDD and did not worsen suicidality or depression, but was associated with
decreased SI and depressive symptoms.
Strengths: Studies using yoga to treat depression have been limited by a lack of manualized yogabased protocols(25), treatment fidelity monitoring(25), and insufficient reporting of safety findings(6).
This randomized dosing study used a manual-driven protocol that was first applied to healthy
controls(10) and was then revised by the addition of the coherent breathing practice when tested in
participants with MDD(9). The yoga instructors attended study meetings to ensure consistency of
delivery, used the manual to conduct each class, and received quarterly compliance feedback from the
PI(9). The teacher training and protocol policy of modifying yoga poses to a participant’s physical
abilities could contribute to the infrequent occurrence and mild nature of study AEs. SI was measured
by two validated and commonly used scales, the BDI-II and C-SSRS. Participants were monitored for
safety by a psychiatrist or clinical psychologist throughout the study. The procedures to maintain
fidelity, excute safety protocols, and capture AEs in this study were clearly documented.
Limitations: The lack of a control group was a limitation, which should be addressed in future RCTs.
The small sample size (N=30) limits generalizability. Physical fitness was not evaluated prior to
randomization such that the effect of physical fitness on AEs could not be evaluated. The findings
cannot be generalized to individuals with more severe depression (BDI-II >40), SI with intent, or a
history of suicide attempts within the past year. Finally, as with previously reported yoga studies(26,27),
the majority of participants were white, educated females; future research would benefit from engaging
more diverse populations.

CONCLUSIONS
In adults with MDD, a 12-week Iyengar yoga plus coherent breathing intervention was
associated with robust reductions in depressive symptoms and SI without intent on the BDI-II
suicide item and C-SSRS in both the LDG and HDG. The intervention had a mild side effect
profile, good tolerability, and a high level of adherence. The most common AE was
musculoskeletal pain. This study provides preliminary data concerning the safety and efficacy
of for yoga-based interventions as a potential treatment for individuals with MDD and SI
without intent. However, larger RCTs with a longer duration are indicated to validate and
extend these preliminary findings.
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